PT - JOURNAL ARTICLE AU - Aggarwal, Shagun AU - Vineeth, Venugopal Satidevi AU - Padwal, Shrutika S. AU - Bhat, Sameer Ahmed AU - Singh, Arpita AU - Kulkarni, Aditya AU - Patil, Mallikarjun AU - Tallapaka, Karthik AU - Pasumarthi, Divya AU - Venkatapuram, Vijayasree AU - Dalal, Ashwin AU - Bhandari, Rashna TI - <em>SERPINA11</em> related novel Serpinopathy- a perinatal lethal disorder AID - 10.1101/2023.10.03.23296272 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.03.23296272 4099 - http://medrxiv.org/content/early/2023/10/03/2023.10.03.23296272.short 4100 - http://medrxiv.org/content/early/2023/10/03/2023.10.03.23296272.full AB - SERPINA11 is a hitherto poorly characterised gene belonging to Clade A of the SERPIN superfamily. The exact functional significance and expression pattern of this gene remains unknown. Here we report a perinatal lethal phenotype associated with biallelic loss of function variants in SERPINA11, and characterised by gross and histopathological features of extracellular matrix disruption. We found SERPINA11 protein expression in multiple mouse tissues and human fetal lungs. Immunofluorescence of the affected fetal lung revealed markedly reduced expression of SERPINA11 protein compared with healthy, gestation matched human fetal lung. Protein expression data from HEK293T cell lines following site directed mutagenesis is also presented to support the loss of function nature of the variant. This novel serpinopathy appears to be a consequence of loss of inhibition of serine proteases involved in extracellular matrix remodelling, revealing SERPINA11 as a protease inhibitor critical for embryonic development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Science and Engineering Research Board (SERB), Government of India (Grant/Award Number: EMR/2016/002478), Department of Health Research (DHR), Government of India (Grant/Award Number: File R.12020/05/2020‐HR/E‐Office:8055238), and CDFD core funds.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Ethics Committee of Nizams Institute of Medical Sciences gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes